false 0001676163 0001676163 2024-06-17 2024-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 17, 2024

 

SS INNOVATIONS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

Florida   333-216054   47-3478854
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

1600 SE 15th Street, #512
Fort Lauderdale, Florida
  33316
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (954) 478-1410

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

As used in this Current Report on Form 8-K (this ”Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.

 

Item 8.01 Other Events.

 

On June 17, 2024, we issued a press release announcing that the Company was recently selected as a finalist in the Surgical Robotics Industry Awards 2024 in the “Outstanding Company” category. 

 

A copy of the press release is included as Exhibit 99.1 to this Report.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated June 17, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 17, 2024 SS INNOVATIONS INTERNATIONAL, INC.
     
  By: /s/ Sudhir Srivastava
    Sudhir Srivastava, M.D.
Chairman and Chief Executive Officer

 

 

2

 

 

 

Exhibit 99.1

 

SS Innovations Designated “Outstanding Company” Finalist for Surgical Robotics Industry Awards 2024

Annual awards celebrate the best of the surgical robotics industry.

 

Fort Lauderdale, FL., June 17, 2024 – Globe Newswire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, was recently selected as a finalist in the Surgical Robotics Industry Awards 2024 in the “Outstanding Company” category. The Company’s SSi Mantra Surgical Robotic System is now at work daily in 40 hospitals in India and at the Johns Hopkins University Hospital Minimally Invasive Surgical Training and Innovation Center (MISTIC), where one system has been installed for clinical training and evaluation purposes.

 

Other finalists in the Outstanding Company category include Intuitive, Medtronic Robotic-Assisted Surgery, CMR Surgical, Distalmotion, KUKA, meerecompany Inc., Meril Healthcare, Moon Surgical and Stryker.

 

The awards celebrate the best of the industry, recognizing the outstanding contributions of organizations, individuals, and technologies across five categories: Outstanding Company, Industry Leadership, Innovative Start-Up, Outstanding Healthcare Provider, and Groundbreaking Technology. The Outstanding Company category highlights outstanding businesses/commercial success, as well as innovative products, processes, services, technologies and procedures. In partnership with Novanta, the Surgical Robotics Industry Awards will be announced on June 26, 2024.

 

“We are honored to be recognized alongside industry giants in robotic surgery and we are equally proud of our Company’s significant growth in such a short time, including the recent milestone of completing 100 robotic cardiac surgeries,” said Dr. Sudhir Srivastava, SS Innovations’ Chairman and CEO. “This accolade from our peers is a testament to our team’s hard work and the impactful benefits our technologies bring to the healthcare community and beyond. As the robotic surgery market continues to flourish, we are further motivated by this recognition as we expand our offerings and reach, aiming to bring these vital technologies to more regions around the world.”

 

SS Innovations’ SSi Mantra Surgical Robotic System provides the capabilities for cardiothoracic, head and neck, gynecology, urology, general surgery and more. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving FDA approval to market and CE Mark approval in 2025.

 

About SS Innovations International, Inc.

 

SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra” its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.

 

 

 

 

About SSi Mantra

 

Supporting advanced, affordable, and accessible robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more. With its modular arm configuration, 3D 4K vision open-console design and superior ergonomics, the system engages with the surgeon and surgical teams to improve safety and efficiency during procedures. SS Innovations has partnered with Johns Hopkins University, installing the SSi Mantra at the University’s Minimally Invasive Surgical Training and Innovation Center (MISTIC) in Baltimore, MD. This installation is actively training new surgeons and promoting the global dissemination of advancements in medical robotics. The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 70 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving FDA approval to market and CE Mark approval in 2025.

 

Forward-Looking Statements

 

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

 

For more information:

 

PCG Advisory

Jeff Ramson

jramson@pcgadvisory.com

 

 

 

 

 

 

 

v3.24.1.1.u2
Cover
Jun. 17, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 17, 2024
Entity File Number 333-216054
Entity Registrant Name SS INNOVATIONS INTERNATIONAL, INC.
Entity Central Index Key 0001676163
Entity Tax Identification Number 47-3478854
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 1600 SE 15th Street
Entity Address, Address Line Two #512
Entity Address, City or Town Fort Lauderdale
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33316
City Area Code 954
Local Phone Number 478-1410
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false

SS Innovations (PK) (USOTC:SSII)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more SS Innovations (PK) Charts.
SS Innovations (PK) (USOTC:SSII)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more SS Innovations (PK) Charts.